- Home
- SLXN vs ONFO Comparison
SLXN vs ONFO Comparison
Compare SLXN & ONFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- ONFO
- Stock Information
- Founded
- SLXN 2008
- ONFO 2018
- Country
- SLXN Israel
- ONFO United States
- Employees
- SLXN N/A
- ONFO N/A
- Industry
- SLXN
- ONFO Computer Software: Programming Data Processing
- Sector
- SLXN
- ONFO Technology
- Exchange
- SLXN NYSE
- ONFO Nasdaq
- Market Cap
- SLXN 6.9M
- ONFO 5.8M
- IPO Year
- SLXN N/A
- ONFO 2022
- Fundamental
- Price
- SLXN $0.95
- ONFO $0.96
- Analyst Decision
- SLXN Strong Buy
- ONFO
- Analyst Count
- SLXN 1
- ONFO 0
- Target Price
- SLXN $5.00
- ONFO N/A
- AVG Volume (30 Days)
- SLXN 1.2M
- ONFO 9.2K
- Earning Date
- SLXN 05-13-2025
- ONFO 05-16-2025
- Dividend Yield
- SLXN N/A
- ONFO N/A
- EPS Growth
- SLXN N/A
- ONFO N/A
- EPS
- SLXN N/A
- ONFO N/A
- Revenue
- SLXN N/A
- ONFO $9,087,118.00
- Revenue This Year
- SLXN N/A
- ONFO N/A
- Revenue Next Year
- SLXN N/A
- ONFO N/A
- P/E Ratio
- SLXN N/A
- ONFO N/A
- Revenue Growth
- SLXN N/A
- ONFO 65.97
- 52 Week Low
- SLXN $0.58
- ONFO $0.61
- 52 Week High
- SLXN $41.85
- ONFO $1.88
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- ONFO 43.22
- Support Level
- SLXN N/A
- ONFO $0.98
- Resistance Level
- SLXN N/A
- ONFO $1.02
- Average True Range (ATR)
- SLXN 0.00
- ONFO 0.04
- MACD
- SLXN 0.00
- ONFO 0.00
- Stochastic Oscillator
- SLXN 0.00
- ONFO 42.86
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.